Interstitial Lung Disease Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions:   Systemic Sclerosis With Lung Involvement;   Systemic Sclerosis;   Interstitial Lung Disease Interventions:   Drug: Mycophenolate Mofetil;   Other: Placebo Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   McGill University;   University of Calgary;   St. Joseph's Healthcare Hamilton;   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR);   Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions:   Systemic Sclerosis With Lung Involvement;   Systemic Sclerosis;   Interstitial Lung Disease Interventions:   Drug: Mycophenolate Mofetil;   Other: Placebo Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   McGill University;   University of Calgary;   St. Joseph's Healthcare Hamilton;   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR);   Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions:   Systemic Sclerosis With Lung Involvement;   Systemic Sclerosis;   Interstitial Lung Disease Interventions:   Drug: Mycophenolate Mofetil;   Other: Placebo Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   McGill University;   University of Calgary;   St. Joseph's Healthcare Hamilton;   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR);   Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions:   Systemic Sclerosis With Lung Involvement;   Systemic Sclerosis;   Interstitial Lung Disease Interventions:   Drug: Mycophenolate Mofetil;   Other: Placebo Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   McGill University;   University of Calgary;   St. Joseph's Healthcare Hamilton;   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR);   Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions:   Systemic Sclerosis With Lung Involvement;   Systemic Sclerosis;   Interstitial Lung Disease Interventions:   Drug: Mycophenolate Mofetil;   Other: Placebo Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   McGill University;   University of Calgary;   St. Joseph's Healthcare Hamilton;   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR);   Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions:   Idiopathic Pulmonary Fibrosis;   Systemic Sclerosis With Lung Involvement Interventions:   Drug: Vixarelimab;   Drug: Placebo Sponsor:   Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions:   Systemic Sclerosis With Lung Involvement;   Systemic Sclerosis;   Interstitial Lung Disease Interventions:   Drug: Mycophenolate Mofetil;   Other: Placebo Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   McGill University;   University of Calgary;   St. Joseph's Healthcare Hamilton;   Jewish General Hospital;   Canadian Institutes of Health Research (CIHR);   Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials